Austedo (deutetrabenazine) / Teva - LARVOL DELTA

When Constipation Becomes a Renal Emergency: Stercoral Proctocolitis With Fecaloma-Induced Bilateral Hydroureteronephrosis and Obstructive Acute Kidney Injury (ACG 2026) - "Her medications included hydroxyzine, carbamazepine, mirtazapine, primidone, pregabalin, deutetrabenazine, and venlafaxine, contributing to a high anticholinergic burden. Massive fecal impaction causing stercoral proctocolitis and obstructive uropathy. Figure Footnote: The distended colon compresses the distal ureters resulting in bilateral hydroureteronephrosis (arrows)."

Acute Kidney Injury • Bipolar Disorder • Cardiovascular • CNS Disorders • Constipation • Endocrine Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypotension • Infectious Disease • Inflammatory Bowel Disease • Movement Disorders • Nephrology • Parkinson's Disease • Renal Disease

Efficacy and Adverse Events of Tetrabenazine, Deutetrabenazine, and Valbenazine in Huntington’s Disease (MDS Congress 2026) - No abstract available

Adverse events • Clinical • CNS Disorders • Movement Disorders

Real-World Evaluation of Deutetrabenazine for Huntington Disease–Associated Chorea in South Korea: Study Design and Baseline Characteristics (MDS Congress 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Movement Disorders

Patient and Caregiver Perspectives on Patient Burden of Huntington Disease Chorea and the Real-World Impact of Deutetrabenazine Treatment (MDS Congress 2026) - No abstract available

Clinical • Real-world • Real-world evidence • CNS Disorders • Movement Disorders

Effectiveness and Safety of Deutetrabenazine in Chinese Patients with Huntington’s Disease-associated Chorea: A Multicenter Phase 4 Study (MDS Congress 2026) - No abstract available

Clinical • P4 data • CNS Disorders • Movement Disorders

Efficacy of Deutetrabenazine in Patients with Tourette Syndrome: A Meta-Analysis of Randomized Controlled Trials (MDS Congress 2026) - No abstract available

Retrospective data • CNS Disorders • Movement Disorders • Tourette Syndrome

Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Tardive Dyskinesia (MDS Congress 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • CNS Disorders • Movement Disorders

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Neurocrine Biosciences | N=50 ➔ 100 | Trial completion date: Jan 2027 ➔ Jun 2028 | Trial primary completion date: Jan 2027 ➔ Jun 2028

Enrollment change • Trial completion date • Trial primary completion date • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Psychiatry • Schizophrenia

A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19-Year-Old Female With Schizophrenia. (PubMed, Clin Case Rep) - "A 19-year-old female with schizophrenia developed severe mixed tardive syndrome (choreoathetoid dyskinesia with prominent tardive dystonia) after antipsychotic treatment, which remained debilitating despite deutetrabenazine, benzodiazepines, baclofen, and amantadine. Over a 39-day inpatient stay, switching the antipsychotic to clozapine and adding botulinum toxin injections plus the central muscle relaxant eperisone led to dramatic improvement, with the Abnormal Involuntary Movement Scale (AIMS) score falling from 32 to 8...This case illustrates that a multimodal strategy-combining a low-D2-affinity antipsychotic, a VMAT2 inhibitor, and targeted muscle relaxation-was associated with marked improvement in this patient with refractory mixed tardive syndrome. However, given the near-simultaneous implementation of multiple interventions, the relative contribution of each component cannot be definitively determined, and controlled studies are needed to establish the efficacy..."

Journal • CNS Disorders • Dystonia • Movement Disorders • Psychiatry • Schizophrenia

Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes. (PubMed, J Cent Nerv Syst Dis) - "Future research should prioritize large-scale randomized trials incorporating rigorous subgroup analyses and extended safety monitoring to assess the distinct role of deutetrabenazine in other types of hyperkinetic movement disorders. This review unpacks the workings of VMAT2 inhibitors, paying particular attention to deutetrabenazine's distinct metabolic profile, and assesses their clinical promise across the range of choreiform disorders to hyperkinetic dystonic syndromes."

Journal • Review • CNS Disorders • Dystonia • Huntington's Disease • Metabolic Disorders • Movement Disorders • Tourette Syndrome

Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study. (PubMed, J Huntingtons Dis) - "Fifty patients had pre- and post-DTBZ TMC scores and reached a stable dose, including 30 with no prior tetrabenazine (TBZ) or DTBZ exposure, 8 with prior TBZ exposure with a switch to DTBZ after a gap, and 9 with prior TBZ exposure with a switch to DTBZ without a gap. Overall, 27 (33.8%) patients had ≥1 adverse event recorded between DTBZ initiation and the first visit with a TMC score after reaching their last stable DTBZ dose or DTBZ discontinuation for those without a stable dose.DiscussionThis real-world study describes improvements in TMC scores among patients with HD-associated chorea treated with DTBZ, regardless of prior treatment. The observed safety profile supports the known safety profile of DTBZ in this population."

HEOR • Journal • Real-world evidence • Retrospective data • CNS Disorders • Genetic Disorders • Huntington's Disease • Movement Disorders

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease (clinicaltrials.gov) - P2/3 | N=30 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Huntington's Disease • Movement Disorders

VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know. (PubMed, Focus (Am Psychiatr Publ)) - "This report reviews efficacy and safety considerations for the two FDA-approved VMAT2 inhibitors, deutetrabenazine and valbenazine, which are recommended as first-line treatment for troublesome TD in current practice guidelines. Overall, these VMAT2 inhibitors offer significant benefit to patients experiencing TD through improved health and quality of life."

Journal • Review • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mood Disorders • Movement Disorders • Psychiatry

Key Innovative brands continued to drive growth while transforming Teva’s portfolio mix and financial profile (The Manila Times) - "AUSTEDO continued to grow rapidly, with global revenues of $696 million, growing 40% YoY in LC; AJOVY global revenues of $244 million, increasing 56% YoY in LC."

Sales • CNS Disorders • Huntington's Disease • Migraine

The nano-intervention in Huntington's disease: A theragnostic approach. (PubMed, Neuroscience) - "Existing medicines which include tetrabenazine, deutetrabenazine, and off-label drugs offer only symptomatic treatment to improve the patient's quality of life and not to treat its root cause. In the last ten years, many clinical trials have been conducted, but no disease-modifying therapy has yet been developed. Researchers across the globe are putting strenuous efforts to develop biomarker-driven strategies for diagnosis and drug delivery technology for treatment of Huntington's disease."

Journal • Review • CNS Disorders • Genetic Disorders • Huntington's Disease • Movement Disorders • Otorhinolaryngology

TD-AIDD: Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (clinicaltrials.gov) - P4 | N=25 | Recruiting | Sponsor: University Hospitals Cleveland Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Behavior Disorders • CNS Disorders • Developmental Disorders • Mental Retardation • Movement Disorders • Psychiatry

HDSA 2026: Austedo’s benefits extend beyond chorea treatment (Huntington’s Disease News) - "Therefore, the Huntington Study Group, a research organization, conducted a real-world, online study involving 192 adult Huntington’s patients and 233 of their caregivers to evaluate the burden of chorea on daily activities, as well as the perceived efficacy of Austedo or Austedo XR treatment...Before treatment, up to 84% of Huntington’s patients said chorea caused social or emotional disruptions or interfered with their participation in work and other everyday activities...After treatment, about three-quarters of patients reported a reduction in chorea severity, and 60% or more said they experienced improvements in social and emotional well-being and participation in everyday activities....After the person they care for started Austedo or Austedo XR, over 78% of caregivers reported improvements in these areas."

Real-world • CNS Disorders • Huntington's Disease

Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis. (PubMed, Biol Pharm Bull) - "Tetrabenazine (TBZ), a vesicular monoamine transporter 2 inhibitor, is commonly used to manage chorea; however, it may exhibit fluctuating plasma levels and elicit frequent adverse events...We compared the safety profiles of TBZ and deutetrabenazine (DTBZ) in real-world clinical practice using disproportionality analysis and the large-scale pharmacovigilance database, VigiBase-the WHO's global database of adverse drug reactions...DTBZ showed fewer adverse event signals and a lower proportion of serious adverse events than TBZ. These findings suggest potential differences in the safety profiles of the two drugs, which may influence tolerability in the treatment of HD."

Adverse events • Journal • CNS Disorders • Dystonia • Huntington's Disease • Movement Disorders • Psychiatry • Sleep Disorder

Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy Participants. (PubMed, Clin Drug Investig) - "The once-daily formulation of deutetrabenazine exhibited dosage strength proportional pharmacokinetics for doses up to 48 mg and there was no observed effect of food."

Journal • CNS Disorders • Huntington's Disease • Movement Disorders

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview. (PubMed, MedComm (2020)) - "Although some deuterated drugs, notably donafenib and deutetrabenazine, have demonstrated clinically significant efficacy, their limited use is an effect of ongoing challenges with metabolic switching and species-specific variation, as well as inadequate mechanistic understanding...Furthermore, the review's discussion includes the current challenges, synthesis, analytical limits, and regulatory considerations that influence further development. Overall, the review offers a strategic roadmap for utilizing deuterium-enabled molecular engineering to accelerate the development of next-generation precision medicine, guiding rational design, innovation toward safer, longer-lasting, and more effective treatments."

Journal • Review • CNS Disorders • Oncology • Rare Diseases • Targeted Protein Degradation

Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Psychopharmacol Bull) - "However, improvements in tic severity did not translate into significant benefits in global clinical impression, quality of life, or depressive symptoms. These findings support the role of deutetrabenazine as a potential adjunctive treatment for selected patients, while underscoring the importance of multimodal management strategies and further long-term studies."

Journal • Retrospective data • Review • CNS Disorders • Depression • Developmental Disorders • Movement Disorders • Psychiatry • Tic Disorders • Tourette Syndrome

Teva Presents New Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea (Teva Press Release) - "Across the real-world survey population, patients reported HD chorea often interfered with social life (71-84%), emotional wellbeing (68-77%), daily activities (70-78%) and vocational/recreational life (67-82%). Caregivers also reported substantial impact across their own social functioning (73–84%), emotional wellbeing (71–84%), daily activities (81–83%) and vocational/recreational life (76-83%) due to their caregiving responsibilities....As a result of movement reduction, over 85% of surveyed patients reported improvements in goals related to daily activities, such as dressing, walking and eating, and goals related to their social lives, such as going out with friends and family."

Clinical data • Real-world • CNS Disorders • Huntington's Disease

Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China (clinicaltrials.gov) - P4 | N=50 | Completed | Sponsor: Teva Branded Pharmaceutical Products R&D LLC

New P4 trial • Real-world evidence • CNS Disorders • Huntington's Disease • Movement Disorders

Beyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review. (PubMed, Eur J Pharmacol) - "Dopaminergic, glutamatergic, and cholinergic drugs exhibit distinct efficacy profiles across various motor and non-motor UHDRS components. This positions them as therapeutic options for attenuating both the motor and non-motor symptoms in HD."

Clinical • Journal • Review • CNS Disorders • Cognitive Disorders • Genetic Disorders • Huntington's Disease • Movement Disorders • Psychiatry

Key Innovative brands continued to drive growth and provide value for patients, while transforming Teva's portfolio mix and financial profile (Teva Press Release) - "AUSTEDO continued to show strong growth, with global revenues of $578 million, growing 41% YoY in LC. AJOVY global revenues of $196 million, increased by 35% YoY in LC. UZEDY revenues of $63 million, increased by 62% YoY in LC. Fastest growing long-acting injectable (LAI)1 has nearly doubled the overall risperidone market since launch. Collectively these brands’ revenues grew by 41% YoY in LC."

Sales • Huntington's Disease • Migraine • Mood Disorders • Schizophrenia